DR. Reddy’s Laboratories Limited income statement RDY

Annual Quarterly

In fiscal 2025, which ended Mar 31, 2025, DR. Reddy’s Laboratories Limited reported revenue of $3.8 billion, up 13.8% from the year before. Net income was $671.0 million, a profit margin of 17.6%. Operating income came to $842.0 million, an operating margin of 22.1%. Diluted earnings per share were $0.79. Across the 8 fiscal years shown, revenue grew from $2.2 billion in fiscal 2018 to $3.8 billion in fiscal 2025, about 8.3% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2025
Mar 31, 2025
FY 2024
Mar 31, 2024
FY 2023
Mar 31, 2023
FY 2022
Mar 31, 2022
FY 2021
Mar 31, 2021
FY 2020
Mar 31, 2020
FY 2019
Mar 31, 2019
FY 2018
Mar 31, 2018
Revenue
3,811
+13.8%
3,350
+12.0%
2,992
+5.9%
2,826
+8.9%
2,594
+12.0%
2,316
+4.1%
2,225
+2.0%
2,181
Cost of revenue
1,581
+14.0%
1,387
+7.0%
1,296
-2.2%
1,325
+11.8%
1,185
+10.9%
1,069
+5.0%
1,018
+0.9%
1,009
Gross profit
2,230
+13.6%
1,963
+15.8%
1,695
+13.0%
1,500
+6.5%
1,409
+13.0%
1,247
+3.4%
1,206
+2.9%
1,172
Research and development
320
+16.8%
274
+16.1%
236
+2.6%
230
+1.8%
226
+10.8%
204
-9.7%
226
-19.6%
281
Selling, general and administrative
1,099
+18.7%
926
+11.8%
828
+1.2%
818
+9.5%
747
+12.3%
665
-5.9%
707
-1.8%
720
Operating income
842
+3.6%
813
+17.0%
695
+78.7%
389
+17.2%
332
+56.6%
212
-29.8%
302
+65.0%
183
Pretax income
900
+4.4%
862
+17.4%
734
+72.3%
426
+18.0%
361
+51.0%
239
-26.5%
325
+47.7%
220
Income tax
229
+18.0%
194
+4.3%
186
+61.7%
115
-8.0%
125
+757.9%
-19
-135.8%
53
-24.3%
70
Net income
671
+0.4%
668
+21.9%
548
+76.2%
311
+31.8%
236
-8.9%
259
-4.8%
272
+80.1%
151
Basic EPS
0.79
-80.3%
4.02
+21.8%
3.30
+76.5%
1.87
+31.7%
1.42
-9.0%
1.56
-4.9%
1.64
+80.2%
0.91
Diluted EPS
0.79
-80.3%
4.01
+21.5%
3.30
+76.5%
1.87
+23.0%
1.52
-2.6%
1.56
-4.9%
1.64
+80.2%
0.91
Weighted average shares, basic
833
+0.1%
832
+0.2%
830
+400.5%
166
+0.0%
166
+0.1%
166
-0.1%
166
+0.0%
166
Weighted average shares, diluted
834
+0.1%
834
+0.2%
832
+400.1%
166
+0.0%
166
+0.1%
166
-0.1%
166
+0.0%
166
Other measures
Interest coverage
25.52x
38.71x
40.88x
29.92x
25.54x
16.31x
17.76x
14.08x
Margins
Gross margin
58.51%
58.60%
56.65%
53.08%
54.32%
53.84%
54.20%
53.74%
Operating margin
22.09%
24.27%
23.23%
13.77%
12.80%
9.15%
13.57%
8.39%
Pretax margin
23.62%
25.73%
24.53%
15.07%
13.92%
10.32%
14.61%
10.09%
Profit margin
17.61%
19.94%
18.32%
11.00%
9.10%
11.18%
12.22%
6.92%
Effective tax rate
25.44%
22.51%
25.34%
27.00%
34.63%
-7.95%
16.31%
31.82%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
RDY (NYSE)
Fiscal year ends
March 31
Incorporated in
India
Headquarters
Hyderabad
SEC filer status
Large accelerated filer
SEC CIK
1135951

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.